Abstract: The invention provides compounds of Formula I: wherein Azabicyclo is where the variables have the definitions discussed herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat a disease or condition in which ?7 is known to be involved.

Abstract: A VEGF responsive cell-based assay for determining VEGF bioactivity is disclosed. The assay utilizes established signal transduction pathways in a method for determining VEGF bioactivity in a sample.

Abstract: This invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs, and solvates thereof wherein X1, R1, R2, R8, R9 and R10 are as defined herein. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1.

Abstract: A pharmaceutical composition containing a glycogen phosphorylase inhibitor of Formula I or IA as defined herein is administered to a mammal to treat infection.

Abstract: The present invention relates to compounds of the formula I, wherein Z1, X, Y, ( )n, R1, R2 and R3 are defined as in the specification, pharmaceutical compositions containing such compounds; and the use of such compounds to treat neurological and gastrointestinal disorders.

Abstract: A corticotropin releasing factor (CRF) antagonist is administered to treat disorders that can be treated by altering circadian rhythm.

Abstract: This invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof wherein X1, X2, R2 and R6 are as defined herein. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1.

Abstract: The present invention provides a compound of the formula: and its pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5 and m are as defined in claim 1. The present invention also provides processes for the preparation thereof, the use thereof in treating cytokines mediated diseases and/or cell adhesion molecules (CAMs) mediated diseases and pharmaceutical compositions for use in such therapy.

Abstract: A process for preparing 2-phenyl-3-aminopyridine, and substituted phenyl derivatives and salts thereof.

Abstract: Compounds of the formula wherein ring A, ring B, ring D, R2, R3, R4, R5, R6, R11, R12, R13, E, G, X and P are as defined below. The compounds of formula I are cholinesterase inhibitors and are useful in enhancing memory in patients suffering from dementia and Alzheimer's disease.

Abstract: The present invention relates to compounds of the formula

Abstract: This invention involves optionally substituted 1,2,3,4,5,6-hexahydro-1,5-methano-pyrido[1,2a][1,5]diazocin-8-one derivatives, their preparation, compositions containing same and method of treating addictive disorders and neurological or mental disorders related to a decrease in cholinergic function.

Abstract: A compound of the formula: and the pharmaceutically acceptable acid addition salts thereof, wherein A is NR1R2, CR1R2R11, or C(═CR1R12)R2, NHCR1R2R11, OCR1R2R11, SCR1R2R11, NHNR1R2, CR2R11NHR1, CR2R11OR1, CR2R11SR1 or C(O)R2; wherein the rest of the variables are herein below defined, used for inflammatory disorders.

Abstract: The present invention relates to alatrofloxacin mesylate substantially free of less polar impurities, to parenteral compositions of alatrofloxacin mesylate and to processes for purifying alatrofloxacin mesylate.

Abstract: Substituted tetralins, chromans and related compounds which, by inhibiting 5-lipoxygenase enzyme and/or blocking leukotriene receptors, are useful in the prevention or treatment of asthma, arthritis, psoriasis, ulcers, myocardial infarction and related disease states in mammals; pharmaceutical compositions comprising said compounds; a method of treatment with said compounds; and intermediates useful in the synthesis of said compounds.

Abstract: A compound of the formula ##STR1## wherein Y and R.sup.1 are defined in the specification, useful in the treatment of arthritis or cancer and other diseases involving selective inhibition of matrix metalloproteinase-13.

Abstract: An improved process, and intermediates, for the preparation of 4'-trifluoromethyl-biphenyl-2-carboxylic acid (1,2,3,4-tetrahydro-isoquinoline-6-yl) amide (I), are disclosed. Compound (I) is useful as an inhibitor of microsomal triglyceride transfer protein and/or apolipoprotein B secretion, and which are accordingly useful for the preparation and treatment of atherosclerosis and its clinical sequelae, for lowering serum lipids, and related diseases.

Abstract: Compounds of the formula ##STR1## wherein ring A, ring B, ring D, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6,R.sup.11, R.sup.12, R.sup.13, E, G, X and P are as defined below. The compounds of formula I are cholinesterase inhibitors and are useful in enhancing memory in patients suffering from dementia and Alzheimer's disease.

Abstract: A compound of the formula ##STR1## wherein n, X, R.sup.3, R.sup.4 and Ar are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, bone resorption, loosening of artificial joint implants, atherosclerosis, multiple sclerosis, occular angiogenisis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF.

Abstract: The present invention provides a compound of formula (I): ##STR1## and a pharmaceutically acceptable salt thereof, wherein Ar is phenylene optionally substituted with halo, hydroxy, cyano, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 halo-substituted alkyl or C.sub.1 -C.sub.4 halo-substituted alkoxy, X is --A--X.sup.1 -- or --X.sup.2 --A--, where A is a direct bond or C.sub.1 -C.sub.4 alkylene, and X.sup.1 is oxy, thio, sulfinyl or sulfonyl; Ar is phenylene, pyridylene or thienylene optionally substituted with halo, hydroxy, cyano, nitro, amino, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 halo-substituted alkyl, C.sub.1 -C.sub.4 halo-substituted alkoxy, C.sub.1 -C.sub.4 alkylamino or di(C.sub.1 -C.sub.4)alkylamino; Y is CN or CONR.sup.1 R.sup.2 wherein R.sup.1 and R.sup.2 are independently hydrogen or C.sub.1 -C.sub.4 alkyl; and R is hydrogen or C.sub.1 -C.sub.6 alkyl; W is C.sub.2 -C.sub.